OC
ACOR

Oppenheimer & Co’s Acorda Therapeutics ACOR Stock Holding History

Oppenheimer & Co’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-159
Closed -$505K – 1390
2015
Q3 		$505K Buy
159
+65
+69% +$252K 0.02% 802
2015
Q2 		$376K Sell
94
-37
-28% -$143K 0.01% 1006
2015
Q1 		$521K Buy
+131
New +$600K 0.01% 850
2014
Q3 		– Sell
-219
Closed -$885K – 1505
2014
Q2 		$885K Buy
+219
New +$893K 0.03% 661

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co's ACOR Position: Q4 2015 in Review

Oppenheimer & Co sold out of Acorda Therapeutics (ACOR) in Q4 2015, closing a stake of 159 shares — an estimated $505K sold.

Oppenheimer & Co first reported a position in ACOR in Q2 2014 and held it in 4 quarters. The position peaked at $885K in Q2 2014. 186 funds tracked by Wall St. Rank hold ACOR as of Q4 2015.

  • Oppenheimer & Co reported no remaining Acorda Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 159 Acorda Therapeutics shares in Q4 2015, an estimated $505K.
  • Oppenheimer & Co first reported a position in Acorda Therapeutics in Q2 2014 and held it in 4 quarters.
  • Oppenheimer & Co's Acorda Therapeutics position peaked at $885K in Q2 2014.
  • 186 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2015.

Based on Oppenheimer & Co's 13F filing for Q4 2015, filed 3 Feb 2016.